Combined general meeting 2025
Category: 2025
Transgene Provides Business and Financial Update for Q1 2025
Q1 financial 2025
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025
AG 2025
Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025
ASCO 2025 curtain
A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
E. J. West et al.Clinical Cancer Research April 2025Download the publication herePublication
Availability of Transgene’s 2024 Universal Registration Document (URD)
URD 2024
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
CTO Appointment
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine – Strong Outlook for 2025
2024 Annual Results
Transgene to Participate in Upcoming Investor Meetings
Investors meetings
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
Eligibility PEA-PME